Compare Adaptive Biotechnologies Corp (ADPT) vs Hasbro, Inc. (HAS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Hasbro, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $25.15 (market cap $4.04B), while Hasbro, Inc. trades at $94.97 (market cap $13.69B). The key difference: Hasbro, Inc. is far larger — about 3.4× Adaptive Biotechnologies Corp's market cap, and Hasbro, Inc. pays a 2.89% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | HAS | |
|---|---|---|
Market Cap | $4.04B | $13.69B |
Sector | Health | Consumer Cyclical |
52-Week High | $25.45 | $105.88 |
52-Week Low | $12.30 | $70.95 |
Enterprise Value | $4.10B | $15.88B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
Hasbro (HAS) trades at $94.49, up 1.04% today, with strong technical and fundamental momentum. The stock exhibits a bullish trend, supported by consecutive earnings beats in Q4 2025, Q1 2026, and Q2 2026. Recent news highlights growth in adult-focused segments like Magic: The Gathering, with Q2 2026 revenue up 16% year-over-year. Valuation metrics show a P/E of 17.27 and P/S of 2.77, while analyst consensus is bullish with a $104.90 price target.
The outlook for Hasbro is positive, driven by IP strength and digital gaming growth, but risks include margin pressures from tariffs and high debt levels. Institutional buying and a 51.52% buy rating from analysts support upside potential, though investors should monitor execution risks and macroeconomic headwinds. The stock's current price is within 5% of its 52-week high, indicating strong near-term momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →
